Correction to "Molecular Aspects of Antitumor Effects of a New Platinum(IV) Drug"
The above article [Kasparkova J, Novakova O, Vrana O, IntiniF, Natile G, and Brabec V (2006) Mol Pharmacol70:1708–1719]describes results obtained exclusively by the authors. Thisarticle also describes some modifications of DNA by cis-[PtCl2(NH3)(1-adamantylamine)].The platinum complex used in this study was from two resources.One sample was synthesized and characterized in the way describedunder Materials and Methods; the other sample of this complexwas obtained from PLIVA-Lachema a.s. (Brno, Czech Republic),which uses the abbreviation LA-9 for this complex and LA-12for its tetravalent analog cis,trans,cis-[PtCl2(CH3COO)2(NH3)(1-adamantylamine)].The results obtained with cis-[PtCl2(NH3)(1-adamantylamine)]from both resources were identical in regard to content, significance,and the extent of the interpretation and conclusions based onthe interpretation mentioned in this article. The fact thatthe results discussed in this article were also obtained withthe complex cis-[PtCl2(NH3)(1-adamantylamine)] (LA-9) obtainedfrom PLIVA-Lachema a.s. was omitted.
The authors regret this omission and apologize for any confusionor inconvenience it may have caused.